Together with prof. Tom Quinn of the University of Missouri-Columbia, Tagworks succeeded in securing an Exploratory/Development grant from the US National Institutes of Health (NIH) Innovative Molecular Analysis Technologies (IMAT) program for the project “In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy”. The proposal was ranked in the top 9% of all applications.
The project will focus on developing new pretargeting strategies for use in alpha-emitter-based radiotherapy of cancer. Prof. Tom Quinn is a world-leading expert on alpha-emitters for therapeutic applications. Combining his expertise with Tagworks’ in vivo pretargeting chemistry approaches offers exciting opportunities for broadening the scope of therapeutically feasible alpha-emitters and enhancing the effectiveness of alpha-emitter radioimmunotherapy by increasing tumor-to-blood ratios.
The grant will be shared between the group of prof. Quinn and Tagworks and has a running time of three years.